Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
69 hedge funds and large institutions have $96.2M invested in Stemline Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 7 closing their positions.
114% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 7
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
48% more call options, than puts
Call options by funds: $253K | Put options by funds: $171K
42% more capital invested
Capital invested by funds: $67.8M → $96.2M (+$28.4M)
13% more funds holding
Funds holding: 61 → 69 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$2.09M |
| 2 |
CCI
Columbus Circle Investors
|
+$1.18M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$797K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$553K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$421K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$6.43M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$3.74M |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$1.21M |
| 4 |
RA
Royce & Associates
New York
|
-$777K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$616K |
STML Hedge Fund Activity: Q3 2016 in Review
69 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q3 2016, worth a combined $96.2M — up 42% from $67.8M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new STML positions and 7 closed out — a net gain of 8 holders — while 23 added to existing stakes and 15 trimmed.
The largest buyer was Candriam SCA, opening a new position worth an estimated $2.09M. The largest seller was TimesSquare Capital Management, exiting entirely with an estimated $6.43M sold.
- 69 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q3 2016, up from 61 in Q2 2016.
- Funds reported $96.2M of Stemline Therapeutics, Inc. stock for Q3 2016, up 42% quarter-over-quarter.
- 15 funds opened new Stemline Therapeutics, Inc. positions in Q3 2016 and 7 closed out, a net change of +8 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q3 2016 was Candriam SCA, an estimated $2.09M added.
- The largest Stemline Therapeutics, Inc. seller in Q3 2016 was TimesSquare Capital Management, an estimated $6.43M sold.
Based on aggregated 13F filings for Q3 2016.